- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04809233
Expanded Access to Tipifarnib
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
To request access, use Responsible Party contact information provided in this record.
Expanded access for tipifarnib is only available in the United States.
Study Overview
Status
Intervention / Treatment
Study Type
Expanded Access Type
- Individual Patients
Contacts and Locations
Study Contact
- Name: Kura Oncology Expanded Access
- Phone Number: (858) 500-8800
- Email: ExpandedAccess@kuraoncology.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion/Exclusion Criteria:
Diagnosed with HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL).
Adult, ages 18+.
Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Expanded Access to Tipifarnib
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
-
Zhejiang Genfleet Therapeutics Co., Ltd.RecruitingRelapsed or Refractory Peripheral T-cell Lymphoma (PTCL)China
-
Fondazione Italiana Linfomi - ETSActive, not recruitingPeripheral T-cell Lymphomas (PTCL) | PTCL-NOS | Angioimmunoblastic T-cell Lymphoma (AITL) | ALK- Anaplastic Large Cell Lymphoma (ALCL) | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell OriginItaly
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Chang... and other collaboratorsNot yet recruitingPeripheral T-cell Lymphomas (PTCL)Taiwan
-
HUYABIO International, LLC.Quintiles, Inc.CompletedPeripheral T-Cell Lymphoma (PTCL)Japan, Korea, Republic of
-
Acrotech Biopharma Inc.Axis Clinicals LimitedCompletedPeripheral T-Cell Lymphoma (PTCL)United States
-
Karyopharm Therapeutics IncTerminatedCutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)Australia, Singapore
-
Royal Marsden NHS Foundation TrustUnknown
-
Institute of Hematology & Blood Diseases HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...RecruitingNon-Hodgkin's Lymphoma (NHL) | Peripheral T Cell Lymphoma (PTCL)China
-
Kyowa Kirin Co., Ltd.CompletedAdult T-Cell Leukemia and Lymphoma (ATL) | Adult Peripheral T-Cell Lymphoma (PTCL)Japan
-
Mundipharma K.K.CompletedRecurrent or Refractory PTCLJapan
Clinical Trials on Tipifarnib
-
Samsung Medical CenterActive, not recruitingUrothelial CarcinomaKorea, Republic of
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
NYU Langone HealthNational Cancer Institute (NCI)Completed
-
University of Maryland, BaltimoreNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditionsUnited States
-
National Cancer Institute (NCI)Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBreast CancerUnited Kingdom, United States, France, Russian Federation, Belgium, Netherlands
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
University Health Network, TorontoNational Cancer Institute (NCI)Completed